MEET AVANCE CLINICAL AT WORLD VACCINE CONGRESS IN WASHINGTON DC, APRIL 1-4 2024
Avance Clinical will attend the World Vaccine Congress in Washington DC, April 1st to 4th, 2024. The World Vaccine Congress has strengthened is the largest and most established vaccine meeting worldwide, since its inception in 2000.
The congress offers a comprehensive platform covering critical topics such as Clinical Development, Bioprocessing & Manufacturing, and Cancer Immunotherapy. The event is set to continue this tradition, bringing together senior and informed industry experts from every corner of the vaccine industry.
Avance Clinical is a specialist full-service CRO for international biotechs that leverages Australia’s supportive clinical trials environment, which includes no IND requirement plus a 43.5% Government incentive rebate on clinical spend.
Avance Clinical is accredited as a gene technology CRO under Australia’s Office of the Gene Technology Regulator (OGTR) which allows it to manage pre-clinical and clinical trials for vaccines and GMO therapies.
The OGTR has developed globally compliant regulations and accreditations to ensure that dealings with genetically modified organisms (GMOs) are safely managed in Australia. The OGTR regulations are very much in line with international guidelines.
Avance Clinical’s Chief Scientific Officer Dr. Gabriel Kremmidiotis said:
“As an OGTR accredited CRO we can guide our international biotech clients with deep knowledge on the OGTR guidelines, allowing us to support our clients minimize delays and risks. Indeed, we would argue the clarity around the OGTR regulations makes Australia one of the most attractive destinations for CGT research,” he said.
About Avance Clinical
Avance Clinical is a full-service CRO for biotechs with a proven track-record for delivering clinical excellence in Australia, New Zealand, and North America. As the largest premium full-service CRO in Australia and North America, Avance Clinical specializes in delivering top-tier clinical trials that yield globally accepted data.
Award-winning CRO for Biotechs
Avance Clinical has been recognized for the fourth consecutive year by Frost & Sullivan in 2023, being awarded the Best Practices Customer Value Leadership for Biotech’s award, for its continuous exceptional performance.
Pre-clinical through to Phase I and Beyond
Avance Clinical offers pre-clinical consultancy services with their experienced ClinicReady team right through to Phase I and beyond clinical services leveraging significant Government incentive rebates of up to 43.5% and rapid start-up regulatory processes that are available in Australia and highly qualified sites and networks within the United States. With experience across more than 110 therapeutic indications, Avance Clinical can deliver world-class, high-quality, internationally accepted data suitable for FDA and EMA review.
Avance Clinical uses state-of-the-art technology and gold-standard systems across all functional areas to provide clients with the most effective processes. Medidata, Oracle, Zelta, Veeva and Medrio are just some of Avance Clinical’s technology partners.